Top of this page
Skip navigation, go straight to the content

UCB off to good start in 2011

  • Posted by

    This means we’re on track to meet expectations of revenues of €3 billion to €3.1 billion for 2011, recurring EBITDA of €650 million to €680 million, and core earnings per share of between €1.60 and €1.70.

    More than 219,000 patients have been treated with UCB’s core medicines for rheumatoid arthritis, Crohn’s disease, epilepsy, Parkinson’s disease and restless legs syndrome in Q1 2011.

    There was good news too from the R&D pipeline. Positive research results on a new therapy for post-menopausal osteoporosis (PMO) – conducted in partnership with Amgen – promise the potential to help the millions of women living with PMO.

    Roch Doliveux, CEO of UCB said that in spite of generic competition – particularly for our mature anti-epilepsy medicine in Europe – from 2012 onwards the company can look forward to a decade that is uninterrupted by patent expirations.

    The divestiture of UCB’s manufacturing businesses in Germany and Italy to Aesica was closed in March 2011. This new partnership is part of UCB’s strategy to optimize its manufacturing network while securing the long-term supply of our products and a long-term future for the sites’ employees.

    Click here to see the press release.

    Forward-looking statements
    This article contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this article.
    Tags:
    Categories:
    Share: